Skip to main navigation Skip to search Skip to main content

A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

  • Strickland, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/52795/MonH-2019-174230(v2)
NMA SSA Reference Number: SSA/52795/MonH-2019-183922(v1)
Monash Health Ref: RES-19-0000-368A
StatusFinished
Effective start/end date17/07/19 → 16/07/25

Keywords

  • phase 3 study
  • colorectal cancer
  • treatment efficacy

Clinical Trial Phase

  • Phase III (a & b)